Get the Stockscreener App
0.8101
4.79%
-0.0408
After Hours:
.80
-0.0101
-1.25%
Rani Therapeutics Holdings Inc stock is traded at $0.8101, with a volume of 832.86K.
It is down -4.79% in the last 24 hours and up +10.08% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
See More
Previous Close:
$0.8509
Open:
$0.821
24h Volume:
832.86K
Relative Volume:
0.89
Market Cap:
$91.05M
Revenue:
$3.17M
Net Income/Loss:
$-36.23M
P/E Ratio:
-1.9817
EPS:
-0.4088
Net Cash Flow:
$-17.11M
1W Performance:
+18.04%
1M Performance:
+10.08%
6M Performance:
-41.30%
1Y Performance:
+52.27%
1-Day Range:
$0.7797
$0.8698
1-Week Range:
$0.6404
$0.9451
52-Week Range:
$0.4404
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.8101 | 95.63M | 3.17M | -36.23M | -17.11M | -0.4088 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Lake Street | Buy |
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Jun-14-24 | Initiated | Maxim Group | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
View All
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
Rani Therapeutics Holdings Inc - TradingKey
Rani Therapeutics Holdings Inc (RANI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rani Therapeutics Holdings Inc (RANI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RANI|Rani Therapeutics Holdings Inc|Price:0.851|Chg%:-0.039 - TradingKey
Rani Therapeutics Hldgs Market Sentiment - Benzinga España
TradingKey - TradingKey
Form 4 Rani Therapeutics Holdings Inc For: 24 July By Investing.com - Investing.com South Africa
Rani Therapeutics director Mir A Imran buys $24,839 in stock By Investing.com - Investing.com Nigeria
Rani Therapeutics director Mir A Imran buys $24,839 in stock - Investing.com
Rani Therapeutics Holdings Inc. (RANI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Rani Therapeutics Holdings Inc (RANI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director IMRAN MIR A - Moomoo
Rani Therapeutics (RANI) insider Imran Mir A buys 36,000 shares - Stock Titan
Rani Therapeutics director, 10% owner Mir A. Imran buys 36,000 shares worth $24,840 - Bitget
Rani Therapeutics Holdings (NASDAQ:RANI) surges 29%, shrinking Nasdaq compliance deficit to 11% - TechStock²
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Form 4 Rani Therapeutics Holdings Inc For: 22 July By Investing.com - Investing.com South Africa
Rani Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Javadi Alireza - Moomoo
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Form 4 Rani Therapeutics Holdings Inc For: 21 July By Investing.com - Investing.com Nigeria
Rani Therapeutics (RANI) CTO records stock sale and tax withholding - Stock Titan
Rani Therapeutics CEO Talat Imran buys $25,193 in stock - Investing.com
Rani Therapeutics CEO Talat Imran buys $25,193 in stock By Investing.com - Investing.com UK
Rani Therapeutics (RANI) CEO purchases 35,000 shares in open-market trade - Stock Titan
Rani Therapeutics (RANI) CEO logs RSU-related tax share sales - Stock Titan
Rani Therapeutics (RANI) grants 2M stock options to its CFO - Stock Titan
Rani Therapeutics’ New CFO Receives 2M-Share Stock Option - Stock Titan
ETFs Investing in Rani Therapeutics Holdings, Inc. Class A Stocks - TradingView
MOLN Stock Price and Chart — NASDAQ:MOLN - TradingView
Rani Therapeutics partners with PegBio on obesity drugs By Investing.com - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Fractyl Health, Inc. (GUTS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing - Sahm
RANI Stock Price, Quote & Chart - ChartMill
Rani Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Rani Therapeutics Tries To Turn Biologic Shots Into Pills - Finimize
Rani TherapeuticsPhase 1B Study Expected t - Moomoo
Rani Therapeutics reports positive Phase 1 data for oral obesity drug - Investing.com South Africa
Rani Therapeutics Reports Positive Initial Phase 1a Data for RT-114 in Obesity - marketscreener.com
Rani Therapeutics Reports Positive Phase 1a Data for Oral RT-114, Achieving Greater Than 150% Systemic Exposure Versus Matched Subcutaneous Dose - Quiver Quantitative
Rani Therapeutics Announces Positive Initial Phase 1a Data - GlobeNewswire
Rani Therapeutics Holdings (RANI) Surges 4.93%: Testing Resistance After Bouncing Off SupportPairs Trade - dars.gov.et
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), GE Healthcare Technologies Inc (GEHC) - The Globe and Mail
PegBio Partners Rani for Oral Metabolic Disease Drugs - AllSci
Rani collaborates with Pegbio on oral drug delivery in obesity - BioWorld News
Why Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration? - Kalkine Media
PegBio Teams with Rani Therapeutics to Pursue Oral Metabolic Therapies - TipRanks
Rani Therapeutics, PegBio Collaborate on Oral Delivery of Obesity Drugs - Moomoo
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):